Beyond ctDNA: EVPs and the Future of Early Cancer Detection, Upcoming Webinar Hosted by Xtalks

In this free webinar, explore the potential of extracellular vesicles and particles (EVPs) as liquid biopsy analytes for early cancer detection. Learn how EVPs differ from circulating tumor DNA and how detecting multiple cancer-associated biomarkers on the same particle can help distinguish tumor-associated signals from background signals. Drawing on findings from ovarian and lung cancer studies, the featured speaker will discuss the opportunities, current evidence, and remaining challenges in translating EVP-based approaches into clinical diagnostics.

TORONTO, Oct. 26, 2026 /PRNewswire/ -- Liquid biopsy has made it possible to detect and characterize cancer from a blood sample, with much of the field focused on circulating tumor DNA (ctDNA). Detecting early-stage disease remains challenging because the amount of ctDNA in circulation can be very low, particularly when tumors are small. This webinar explores how extracellular vesicles and particles (EVPs) offer another route to accessing tumor-derived molecular information for early cancer detection.

EVPs are shed continuously by living cells and carry proteins, nucleic acids and other molecular cargo that reflect their cell of origin. However, because healthy cells also release EVPs, distinguishing tumor-associated particles from the normal background remains a key challenge.

This webinar explores EVPs as a complementary class of liquid biopsy analytes for early cancer detection. The featured speaker will discuss EVP biology, how they differ from other liquid biopsy analytes and the rationale for measuring multiple cancer-associated biomarkers colocalized on individual EVPs rather than measuring each biomarker independently.

The featured speaker will examine how identifying combinations of cancer-associated biomarkers on the same EVP may improve specificity. Individual biomarkers are rarely specific to cancer on their own, but detecting multiple cancer-associated markers on the same particle may provide a more distinctive biological signature than measuring individual markers independently.

Ovarian and lung cancer research programs will illustrate how this approach is being evaluated across cancer types and clinical settings, including an evaluation of prospectively collected samples from a large, randomized screening trial. The featured speaker will discuss the scientific rationale, evidence generated to date and remaining questions as EVP-based diagnostics continue to develop.

Register for this webinar to learn how EVPs could expand liquid biopsy beyond ctDNA and support earlier cancer detection.

Join Toumy Guettouche, PhD, Chief Scientific Officer, Mercy Bio, for the live webinar on Monday, November 9, 2026, at 1pm EST (10am PST).

For more information, or to register for this event, visit Beyond ctDNA: EVPs and the Future of Early Cancer Detection.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks